Next-generation drugs, diagnostics, and technologies to solve urgent medical needs
SRI Biosciences develops transformative approaches and platforms for challenging therapeutic problems. We conduct basic and translational research, have the breadth — and depth — to deliver the latest in biomedical research through technology development.
Our researchers have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
200+Research and technical staff(40% PhDs)
200+Biomedical products moved to clinical trials
11Partnerships with National Institutes of Health Divisions
“Because we’re a nonprofit with a mission to make the world a better place, there’s a lot of flexibility in the types of projects we can pursue. We can do earlier stage research that may have higher impact without as much emphasis on the bottom line. And when we collaborate with pharmaceutical companies, it’s truly a co-development process—sharing expertise and innovating together.”Kathlynn Brown, PhDPresident – Biosciences Division
New ways of thinking about human health
Uncommon in the world of tech development, SRI Biosciences brings together basic bioscience, applied research for early-stage IP generation, and translational development — moving the lab to the real world.
Our Human Sleep Lab is studying sleep’s impact on women’s health among other current themes. Sleep biology also explores medical neuroimaging advancements and preclinical sleep research.
Our biopharma R&D services dive deep into preclinical drug development. We also bring expertise in automated chemistry design; medicinal chemistry and synthesis; and licensable drugs.
We invent some of the world’s leading technology and tools to create new precision medicine possibilities: FOX Three Molecular Guidance System (MGS), DiaCyt, TALL, Techneins, and more.
Organizations work with SRI Biosciences to innovate around biomarker and biological assay development, biohazard detection devices, and health-monitoring wearables.
SRI joins a nationwide network aiming to accelerate transformative health solutions.
The director of SRI’s Center for Health Sciences works with other labs to solve sleep issues by integrating cutting-edge technologies.
The cancer targeting molecule was discovered through SRI’s FOX Three Molecular Guidance System.
SRI Biosciences’ highly specialized platforms marry the advantages of our cutting-edge research with our flexible biotech business model. Partner with us to leverage our rigorous early discovery and development to customize your specific applications.
Cell-selective, intracellular delivery of macromolecular therapeutics: Deliver essentially any cargo to selected cell types, and internalize into those cells to targeted subcellular locations.
A new immunotherapy with the potential to overcome current challenges and extend the benefits of immunotherapy to many more patients.
Identification of peptide-based delivery agents that can selectively transport molecular cargos into the central nervous system without physically disrupting the blood-brain barrier.
A rapid discovery platform for non-natural polymers that expands our access to 3-dimensional structural diversity with the synthetic accessibility and optimizability of small molecules.
Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy
Here, we determined the activity dynamics of orexin neurons during sleep that suppress the abnormal REM sleep architecture of narcolepsy.
Identification and characterization of screen use trajectories from late childhood to adolescence in a US-population based cohort study
This study will identify and characterize the subgroups of adolescents sharing similar trajectories of screen use from childhood to adolescence.
We describe here a model of opioid withdrawal in mice that resembles the sleep phenotype characteristic of withdrawal in humans.